EIKNEikon TherapeuticsSigning up patients
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
Advanced Solid Tumors
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 130 (planned)
- Started
- Apr 30, 2025
- Main results expected
- Dec 2028
- Fully finished
- Dec 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants who experience a Dose-Limiting Toxicity (DLT)
Measured over: (Timeframe: up to 28 days)
Number of participants with adverse events, treatment emergent adverse events or serious adverse events
Measured over: (Time Frame: 1 month post last dose of EIK1004 (IMP1707)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06907043 · record last updated 2025-08-19 · checked 2026-11-09 15:47 UTC